Pharsight

Drugs that contain Cannabidiol

1. Epidiolex patents expiration

EPIDIOLEX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10195159 JAZZ PHARMS RES Processes and apparatus for extraction of active substances and enriched extracts from natural products
May, 2022

(2 years ago)

US11096905 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Oct, 2035

(11 years from now)

US11207292 JAZZ PHARMS RES Cannabidiol preparations and its uses
Apr, 2039

(14 years from now)

US11865102 JAZZ PHARMS RES Cannabidiol preparations and its uses
Apr, 2039

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9956186 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10092525 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US9949937 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10111840 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11633369 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10603288 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11357741 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10709671 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10709674 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US9956183 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US9956184 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US9956185 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10137095 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11766411 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10709673 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11154516 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10849860 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11311498 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10966939 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11446258 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11701330 JAZZ PHARMS RES Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11400055 JAZZ PHARMS RES Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(11 years from now)

US11065209 JAZZ PHARMS RES Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(11 years from now)

US10918608 JAZZ PHARMS RES Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(11 years from now)

US11406623 JAZZ PHARMS RES Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
Mar, 2041

(16 years from now)

US11160795 JAZZ PHARMS RES Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
Mar, 2041

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-216) Sep 28, 2025
Orphan Drug Exclusivity(ODE-332) Jul 31, 2027
Orphan Drug Exclusivity(ODE-326) Jul 31, 2027
M(M-270) Oct 20, 2026
New Chemical Entity Exclusivity(NCE) Sep 28, 2023
New Patient Population(NPP) Jul 31, 2023

NCE-1 date: 28 September, 2022

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of convulsive seizures in patients with lennox gastaut syndrome; Use for the treatment of drop seizures in patients with dravet syndrome; Use in combination with clobazam for the...

Dosage: SOLUTION;ORAL

How can I launch a generic of EPIDIOLEX before it's drug patent expiration?
More Information on Dosage

EPIDIOLEX family patents

Family Patents